AVIR NASDAQ
Credit Risk of going bust: lower than 90% of companies Debt: 0.1% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.00 (down more than 99.9%), Atea Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $424K against a stock market value of $333.7M.
Distance to default 14.08 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $212K (short-term plus half of long-term), stock volatility 51.7%; Altman Z'' -0.12. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Boston, MA 02110
US
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Lucidi Bruno | M-Exempt | 29,600 | — | 2026-06-18 |
| Lucidi Bruno | M-Exempt | 29,600 | — | 2026-06-18 |
| Lucidi Bruno | A-Award | 26,700 | — | 2026-06-18 |
| Lucidi Bruno | A-Award | 37,700 | $4.36 | 2026-06-18 |
| BERGER FRANKLIN M | M-Exempt | 29,600 | — | 2026-06-18 |